Open Access<p>Pharmacokinetics, Efficacy and Safety of a Plasma-Derived VWF/FVIII Concentrate (Formulation V) in Pediatric Patients with von Willebrand Disease (SWIFTLY-VWD Study)</p>
Author(s) -
G. Auerswald,
Claudia Djambas Khayat,
Oleksandra Stasyshyn,
Genadi Iosava,
I. P. Romashevskaya,
Marta Julia López,
Wilfried Seifert,
Tobias Rogosch
Publication year - 2020
Publication title -
journal of blood medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.676
H-Index - 18
ISSN - 1179-2736
DOI - 10.2147/jbm.s236789
Subject(s) - medicine , von willebrand factor , adverse effect , pharmacokinetics , von willebrand disease , incidence (geometry) , gastroenterology , pediatrics , platelet , optics , physics
Formulation V (VONCENTO ® ) is a plasma-derived high-concentration/low-volume, high-purity von Willebrand factor (VWF)/factor VIII (FVIII) concentrate, originally indicated for von Willebrand disease (VWD) in adults and adolescents. This multicenter, open-label study (SWIFTLY-VWD) evaluated the pharmacokinetics (PK), as well as hemostatic efficacy and safety, of Formulation V in pediatric patients (<12 years) with severe VWD requiring treatment or prophylaxis of bleedings.